Investors should invest in CORT right now as the stock is doing extremely well in 2024 and its prospects look even brighter.

Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Corcept Therapeutics Inc. (CORT), which posted strong financial results for the third quarter yesterday, is anticipating a ...

On Monday, Corcept Therapeutics Incorporated (CORT) stock saw a modest uptick, ending the day at $50.06 which represents a slight increase of $2.44 or 5.12% from the prior close of $47.62. The stock ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Corcept Therapeutics (CORT – Research Report). The ...

Corcept Therapeutics (NASDAQ:CORT) is gearing up to announce its quarterly earnings on Wednesday, 2024-10-30. Here's a quick overview of what investors should know before the release. Analysts are ...

Corcept's Phase 3 GRADIENT trial for relacorilant has missed its primary endpoint – the improvement in SBP for Cushing's ...

The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 27 cents per share. The drug developer posted revenue of $182.5 million in the period, which also beat ...

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a ...

List today: American Assets Trust, Inc. AAT: This self-administered real estate investment trust has seen the Zacks Consensus ...